MELD-XI score and cardiac mortality or transplantation in patients after Fontan surgery
- Gabriele Egidy Assenza1,2,3,
- Dionne A Graham1,
- Michael J Landzberg1,2,
- Anne Marie Valente1,2,
- Michael N Singh1,2,
- Aamir Bashir1,
- Susan Fernandes1,
- Koenraad J Mortele4,
- Chinweike Ukomadu5,
- Massimo Volpe3,6,
- Fred Wu1,2
- 1Department of Cardiology, Boston's Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 2Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 3Department of Clinical and Molecular Medicine, Sant'Andrea Hospital, “Sapienza Universita’ di Roma” University, Rome, Italy
- 4Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
- 5Division of Gastroenterology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
- 6IRCCS Neuromed, Pozzilli, Italy
- Correspondence to Dr Gabriele Egidy Assenza, Boston Adult Congenital Heart (BACH) and Pulmonary Hypertension Program, Brigham and Women's Hospital, Boston's Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA;
- Received 9 November 2012
- Revised 7 January 2013
- Accepted 10 January 2013
- Published Online First 13 February 2013
Objective The Fontan operation is a staged palliation for complex congenital heart disease and single ventricle physiology. Perioperative survivors of the Fontan operation experience long-term cardiac complications, including death. Liver and renal dysfunction are reported in these patients and have a direct effect on morbidity and mortality. This study aims to investigate whether the Model for End-stage Liver Disease eXcluding INR score (function of creatinine and total bilirubin, MELD-XI) predicts risk for cardiac mortality or transplantation in patients with Fontan circulation.
Design and setting Retrospective, single-centre study. Time of first evaluation was the time of the earliest available MELD-XI score measurement, and follow-up was terminated by a cardiac event or by the last clinical evaluation.
Patients Patients surviving after Fontan surgery and evaluated at Boston Children's Hospital between 1993 and 2008.
Main outcome measure Composite endpoint of sudden death, death from congestive heart failure or cardiac transplantation.
Results The MELD-XI score was calculated as MELD-XI=11.76(loge creatinine)+5.112(loge total bilirubin)+9.44. Ninety-six patients were included (52 male, median age 26 years). After a mean follow-up period of 5.7 years, 18 patients (19%) experienced the composite end point. Baseline MELD-XI score was independently and directly related to the incidence of the composite endpoint (HR for high MELD-XI score group of 7.76, 95% CI 2.05 to 29.33, p=0.008).
Conclusions Fontan patients with a higher MELD-XI score have shorter freedom from sudden cardiac death, death from congestive heart failure and cardiac transplantation.